Scientists in the Anderson Lab are developing implants containing cells engineered to manufacture therapeutic proteins, acting as long-term, renewable drug supplies for treating chronic diseases. The next generation of these living implants integrates bioelectronics that use light to communicate with cells, instructing them when and how much drug to produce. This approach enables on-demand dosage control tailored to the patient’s health needs.

Here, an incubator houses hybrid bioelectronic–living implants cultured in Petri dishes on raised platforms. A near-field communication (NFC) antenna beneath each platform transmits power to the implants using the same technology as consumer wireless charging devices. The emitted light activates gene circuits in engineered cells, allowing researchers to remotely regulate therapeutic production.